Insider Selling: BiomX (NYSEAMERICAN:PHGE) Director Sells $2,650,000.00 in Stock

BiomX Inc. (NYSEAMERICAN:PHGE) Director Reuven Yeganeh sold 530,000 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $5.00, for a total value of $2,650,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Reuven Yeganeh also recently made the following trade(s):

• On Monday, March 16th, Reuven Yeganeh sold 450,000 shares of BiomX stock. The shares were sold at an average price of $5.00, for a total value of $2,250,000.00.

BiomX Stock Performance

NYSEAMERICAN PHGE opened at $4.89 on Friday. The business has a 50 day simple moving average of $5.03 and a 200 day simple moving average of $6.31. BiomX Inc. has a 52-week low of $1.50 and a 52-week high of $14.71. The stock has a market cap of $7.78 million, a price-to-earnings ratio of -0.19 and a beta of 1.68.

BiomX (NYSEAMERICAN:PHGE) last announced its quarterly earnings results on Thursday, February 19th. The company reported $6.99 earnings per share for the quarter. On average, analysts predict that BiomX Inc. will post -2.77 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. purchased a new position in shares of BiomX Inc. (NYSEAMERICAN:PHGE) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned about 5.99% of BiomX as of its most recent SEC filing. 40.57% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered shares of BiomX from a “buy” rating to a “hold” rating in a research note on Monday, March 9th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.